Efficacy of Daratumumab Containing Regimens Post Lenalidomide Maintenance in Transplant Eligible Patients: Real-World Experience from the Canadian Myeloma Research Group Database by LaurenEBS | Dec 13, 2020
Part 1 Results of a Dose Finding Study of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) by LaurenEBS | Dec 13, 2020
A Phase 2 Study of Belantamab Mafodotin (GSK2857916) in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma (RRMM): Results for Part 1 Dose Finding by LaurenEBS | Jun 13, 2020
A Randomized Phase II, Open Label, Study of Daratumumab, Weekly Low-Dose Oral Dexamethasone and Cyclophosphamide with or without Pomalidomide in Patients with Relapsed and Refractory Multiple Myeloma by LaurenEBS | Dec 13, 2019
Treatment of Multiple Myeloma Patients Progressing on Lenalidomide-Based Regimens by LaurenEBS | Dec 13, 2019
